• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

托伐普坦治疗重症新生儿常染色体显性多囊肾病

Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease.

作者信息

Gilbert Rodney D, Evans Hazel, Olalekan Kazeem, Nagra Arvind, Haq Mushfequr R, Griffiths Mark

机构信息

Regional Paediatric Nephro-Urology Unit, Southampton Children's Hospital, Tremona Road, Southampton, SO16 6YD, Hampshire, UK.

Faculty of Medicine, University of Southampton, Southampton, UK.

出版信息

Pediatr Nephrol. 2017 May;32(5):893-896. doi: 10.1007/s00467-017-3584-9. Epub 2017 Feb 13.

DOI:10.1007/s00467-017-3584-9
PMID:28194574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5368203/
Abstract

BACKGROUND

Severe neonatal autosomal-dominant polycystic kidney disease (ADPKD) is rare and easily confused with recessive PKD. Managing such infants is difficult and often unsuccessful.

CASE DIAGNOSIS/TREATMENT: A female infant with massive renal enlargement, respiratory compromise and hyponatraemia was treated with the arginine vasopressin receptor 2 antagonist tolvaptan. This resolved hyponatraemia, and there was no further increase in renal size.

CONCLUSION

Tolvaptan may be a useful treatment for severe neonatal PKD.

摘要

背景

严重的新生儿常染色体显性多囊肾病(ADPKD)较为罕见,且易与隐性多囊肾病相混淆。治疗此类婴儿难度较大,且往往不成功。

病例诊断/治疗:一名患有巨大肾肿大、呼吸功能不全和低钠血症的女婴接受了精氨酸加压素受体2拮抗剂托伐普坦治疗。这纠正了低钠血症,且肾脏大小未进一步增大。

结论

托伐普坦可能是治疗严重新生儿多囊肾病的一种有效疗法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2261/5368203/522d568ebf1c/467_2017_3584_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2261/5368203/522d568ebf1c/467_2017_3584_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2261/5368203/522d568ebf1c/467_2017_3584_Fig1_HTML.jpg

相似文献

1
Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease.托伐普坦治疗重症新生儿常染色体显性多囊肾病
Pediatr Nephrol. 2017 May;32(5):893-896. doi: 10.1007/s00467-017-3584-9. Epub 2017 Feb 13.
2
Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.托伐普坦对不同基因突变的常染色体显性多囊肾病患者肾脏受累的影响。
Clin Exp Nephrol. 2021 Mar;25(3):251-260. doi: 10.1007/s10157-020-01988-4. Epub 2020 Nov 3.
3
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.托伐普坦对不同肾功能水平常染色体显性多囊肾病个体的短期疗效。
Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15.
4
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.TEMPO(托伐普坦治疗常染色体显性遗传多囊肾病及其结局的疗效和安全性)3-4 研究的原理和设计。
Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17.
5
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.一项关于托伐普坦治疗常染色体显性遗传性多囊肾病安全性和有效性的临床试验的基本原理与设计
Am J Nephrol. 2017;45(3):257-266. doi: 10.1159/000456087. Epub 2017 Feb 7.
6
Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.遗传学可能预测托伐普坦治疗常染色体显性遗传多囊肾病的疗效。
Am J Nephrol. 2020;51(9):745-751. doi: 10.1159/000509817. Epub 2020 Aug 12.
7
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.托伐普坦对常染色体显性多囊肾病患者肾功能和容量的短期影响。
Kidney Int. 2011 Aug;80(3):295-301. doi: 10.1038/ki.2011.119. Epub 2011 May 4.
8
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.尿渗透压、对托伐普坦的反应以及常染色体显性多囊肾病的预后:TEMPO 3:4试验结果
J Am Soc Nephrol. 2017 May;28(5):1592-1602. doi: 10.1681/ASN.2016040448. Epub 2016 Dec 5.
9
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.能否进一步丰富常染色体显性遗传多囊肾病快速进展患者的临床试验?PROPKD 评分在 TEMPO 试验中的应用。
Nephrol Dial Transplant. 2018 Apr 1;33(4):645-652. doi: 10.1093/ndt/gfx188.
10
Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.托伐普坦对不同慢性肾脏病分期常染色体显性遗传性多囊肾病患者短期肾血流动力学的影响。
Kidney Int. 2013 Dec;84(6):1278-86. doi: 10.1038/ki.2013.285. Epub 2013 Jul 31.

引用本文的文献

1
Long-term tolvaptan therapy in a case of very early-onset polycystic kidney disease.长期使用托伐普坦治疗一例极早发型多囊肾病
Pediatr Nephrol. 2025 Mar 1. doi: 10.1007/s00467-025-06732-2.
2
A case of hyponatraemia cured by delivery.一例因分娩治愈的低钠血症病例。
Obstet Med. 2025 Jun;18(2):103-106. doi: 10.1177/1753495X241247942. Epub 2024 Apr 24.
3
A child with TSC2/PKD1 contiguous gene deletion syndrome successfully treated with tolvaptan for rapidly enlarging renal cysts.一名患有 TSC2/PKD1 连续基因缺失综合征的儿童,经托伐普坦治疗后迅速增大的肾囊肿得到成功缓解。

本文引用的文献

1
Bilineal inheritance of PKD1 abnormalities mimicking autosomal recessive polycystic disease.PKD1 异常的双线性遗传,模拟常染色体隐性多囊肾病。
Pediatr Nephrol. 2013 Nov;28(11):2217-20. doi: 10.1007/s00467-013-2484-x. Epub 2013 Apr 28.
2
Type of PKD1 mutation influences renal outcome in ADPKD.PKD1 突变类型影响 ADPKD 的肾脏结局。
J Am Soc Nephrol. 2013 May;24(6):1006-13. doi: 10.1681/ASN.2012070650. Epub 2013 Feb 21.
3
Tolvaptan in patients with autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性遗传多囊肾病。
CEN Case Rep. 2024 Oct;13(5):351-355. doi: 10.1007/s13730-024-00854-6. Epub 2024 Feb 27.
4
Modifiers of Autosomal Dominant Polycystic Kidney Disease Severity: The Role of Hypomorphic Alleles.常染色体显性遗传多囊肾病严重程度的修饰因子:低功能等位基因的作用。
Genes (Basel). 2023 Jun 7;14(6):1230. doi: 10.3390/genes14061230.
5
Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.托伐普坦治疗常染色体显性遗传多囊肾病患儿和青少年患者的随机对照试验
Clin J Am Soc Nephrol. 2023 Jan 1;18(1):36-46. doi: 10.2215/CJN.0000000000000022.
6
Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?托伐普坦用于儿童常染色体显性多囊肾病:何去何从?
Kidney Dis (Basel). 2021 Sep;7(5):343-349. doi: 10.1159/000517186. Epub 2021 Jul 2.
7
Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease.托伐普坦治疗常染色体显性遗传性多囊肾病的安全性概况
Ther Clin Risk Manag. 2021 Jun 29;17:649-656. doi: 10.2147/TCRM.S286952. eCollection 2021.
8
Tolvaptan Response in a Hyponatremic Newborn with Syndrome of Inappropriate Secretion of Antidiuretic Hormone.抗利尿激素分泌不当综合征导致的低钠血症新生儿对托伐普坦的反应
Case Rep Pediatr. 2021 May 12;2021:9920817. doi: 10.1155/2021/9920817. eCollection 2021.
9
The wind of change in the management of autosomal dominant polycystic kidney disease in childhood.儿童常染色体显性遗传性多囊肾病管理的变革之风。
Pediatr Nephrol. 2022 Mar;37(3):473-487. doi: 10.1007/s00467-021-04974-4. Epub 2021 Mar 7.
10
Demographic and clinical characteristics of children with autosomal dominant polycystic kidney disease: a single center experience.常染色体显性遗传性多囊肾病患儿的人口统计学和临床特征:单中心经验。
Turk J Med Sci. 2021 Apr 30;51(2):772-777. doi: 10.3906/sag-2009-79.
N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3.
4
Neonatal onset autosomal dominant polycystic kidney disease (ADPKD) in a patient homozygous for a PKD2 missense mutation due to uniparental disomy.常染色体显性遗传多囊肾病(ADPKD)新生儿发病患者,由于单亲二体导致 PKD2 错义突变纯合子。
J Med Genet. 2012 Jan;49(1):37-40. doi: 10.1136/jmedgenet-2011-100452. Epub 2011 Nov 23.
5
Mutations in multiple PKD genes may explain early and severe polycystic kidney disease.多种 PKD 基因的突变可能解释了多囊肾病的早期和严重病变。
J Am Soc Nephrol. 2011 Nov;22(11):2047-56. doi: 10.1681/ASN.2010101080. Epub 2011 Oct 27.
6
Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases.多囊蛋白-2 和磷酸二酯酶 4C 是纤毛 A 激酶锚定蛋白复合物的组成部分,该复合物在囊性肾病中被破坏。
Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10679-84. doi: 10.1073/pnas.1016214108. Epub 2011 Jun 13.
7
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.托伐普坦对常染色体显性多囊肾病患者肾功能和容量的短期影响。
Kidney Int. 2011 Aug;80(3):295-301. doi: 10.1038/ki.2011.119. Epub 2011 May 4.
8
Magnetic resonance imaging of kidney and cyst volume in children with ADPKD.磁共振成像在儿童多囊肾病中对肾脏和囊肿体积的评估。
Clin J Am Soc Nephrol. 2011 Feb;6(2):369-76. doi: 10.2215/CJN.03780410. Epub 2010 Nov 29.
9
Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. copeptin,一种加压素的替代标志物,与常染色体显性遗传性多囊肾病的疾病严重程度相关。
Clin J Am Soc Nephrol. 2011 Feb;6(2):361-8. doi: 10.2215/CJN.04560510. Epub 2010 Oct 7.
10
Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD.不完全外显的 PKD1 等位基因模拟 ARPKD 的肾脏表现。
J Am Soc Nephrol. 2010 Jul;21(7):1097-102. doi: 10.1681/ASN.2009101070. Epub 2010 Jun 17.